Cerebral Oxymetry and Neuronal Markers in Newborns and Infants Undergoing Surgery (NEMARKO)

December 12, 2015 updated by: Danguole C Rugyte, Lithuanian University of Health Sciences

Cerebral Oxymetry and Neuronal Biomarkers in Newborns and Infants During Perioperative Period

The purpose of this study is to assess whether peri-operative period in neonates and infants is associated with an increase in blood biomarkers, specific for neuronal injury, and to correlate them with clinical variables and sedative/analgesic agents. Patients, who meet inclusion criteria and does not meet exclusion criteria, are enrolled. Blood samples for measurement serum concentrations of markers (S100-B and Neuron-Specific Enolase (NSE)) are drawn before surgery (baseline) and on the 1-st, 2-nd and 3-rd day after surgery. During surgery cerebral oxygenation (rSO2) monitoring is continuously applied; rSO2, hemodynamic and respiratory values are simultaneously recorded every 5 minutes. Anesthesia, pre and postoperative treatment, including analgesia and sedation, are given as per standard of care.

Study Overview

Detailed Description

Retrospective studies have shown that surgery in infancy is associated with worse neurodevelopmental outcome, compared to general population. The reasons may be complex, and patients at risk are unknown. Brain growth and central nervous system formation are extremely active in neonates and infants. Metabolic or circulatory derangement may have negative influence on the developing brain. Disease and perioperative period, both may further put this population at risk for physiological abnormalities. Near infrared spectroscopy was shown to be a convenient method for monitoring of cerebral tissue oxygenation during surgery.

The great majority of anesthetics and sedative drugs, used in perioperative period, were shown to cause neuronal apoptosis in experimental animals. Some studies found that neurological marker S-100B increased in cerebrospinal fluid and blood immediately following anesthesia in animals. Several clinical studies supported this founding in children following cardiac and general surgery.

The aim of this study is to assess the dynamics of S-100B protein pre- and during 72 hours after surgery in neonates and infants aged 1-93 days, operated for abdominal/thoracic/urologic malformations/disease. As S-100B in blood may have extracranial sources, we simultaneously assess other neuronal marker Neuron-specific Enolase.

Study Type

Interventional

Enrollment (Actual)

49

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Kaunas, Lithuania, 50009
        • Lithuanian University of Health Sciences Kaunas Clinics

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

No older than 3 months (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • patients, undergoing general, thoracic, urological surgery for congenital anomalies or disease
  • signed written informed consent by parents/official caregivers

Exclusion Criteria:

  • cardiac surgery
  • any evidence of neurological disease
  • sepsis
  • limited ability to obtain blood samples
  • clinically significant anemia
  • physical status of the patients corresponding to American Society of Anesthesiologists (ASA) class 4 and 5.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Screening
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: neonates and infants requiring surgery
neonates and infants in whom blood samples for measurement of S-100 B protein in serum and NSE protein in serum are taken pre-operatively and 1-st, 2-nd and 3-rd post-operatively. During anesthesia cerebral near infrared spectroscopy is continuously applied until the wound closure.
At the start of anesthesia on the patient's forehead two electrodes are attached the for continuous measurement of cerebral near infrared spectroscopy during surgery.
Other Names:
  • cerebral tissue oxygen saturation
  • cerebral oxymetry
0,5-1 ml of blood from periferal site for determination of serum S-100B concentration.
Other Names:
  • S-100B protein in blood
0,5-1 ml of blood from periferal site for determination of serum NSE concentration.
Other Names:
  • Neuron-specific Enolase in blood

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
change in S-100B and NSE concentrations in serum
Time Frame: within 24 hours and 3 days after surgery
change in S-100B and NSE concentrations in serum compared to preoperative value
within 24 hours and 3 days after surgery

Secondary Outcome Measures

Outcome Measure
Time Frame
association of S-100B and NSE concentrations in serum with intraoperative cerebral near infrared spectroscopy values.
Time Frame: within 24 hours after surgery
within 24 hours after surgery

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
association of S-100B and NSE concentrations in serum with cumulative doses of sedative agents
Time Frame: within 24 hours pre surgery to 3 days after surgery
Pre and postoperative S-100B and NSE concentrations in serum will be correlated with the administered pre and postoperative cumulative doses of sedatives and analgesics
within 24 hours pre surgery to 3 days after surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Danguole C Rugyte, MD. PhD, Lithuanian University of Health Sciences

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

March 1, 2013

Primary Completion (Actual)

November 1, 2015

Study Completion (Actual)

November 1, 2015

Study Registration Dates

First Submitted

April 17, 2015

First Submitted That Met QC Criteria

April 17, 2015

First Posted (Estimate)

April 22, 2015

Study Record Updates

Last Update Posted (Estimate)

December 15, 2015

Last Update Submitted That Met QC Criteria

December 12, 2015

Last Verified

December 1, 2015

More Information

Terms related to this study

Other Study ID Numbers

  • BE-2-43

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Newborn, Infant, Disease

Clinical Trials on Cerebral near infrared spectroscopy

3
Subscribe